{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:43:11Z","timestamp":1791132191941,"version":"4.1.0"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Picornaviruses (PV) include human rhinovirus (HRV), the primary cause of the common cold, and the enteroviruses (EV), which cause serious diseases such as poliomyelitis, meningoencephalitis, and systemic neonatal disease. Although no compounds for PV infections have been approved in the United States, pirodavir was one of the most promising capsid-binding compounds to show efficacy in human clinical trials for chemoprophylaxis of the common cold. Susceptibility to hydrolysis precluded its use as an oral agent. We have developed orally bioavailable pyridazinyl oxime ethers that are as potent as pirodavir. Compounds BTA39 and BTA188 inhibited a total of 56 HRV laboratory strains and three clinical isolates as determined by neutral red uptake assay. At concentrations of &lt;100 nM, BTA39 inhibited 69% of the HRV serotypes and isolates evaluated, BTA188 inhibited 75%, and pirodavir inhibited 59% of the serotypes and isolates. The 50% inhibitory concentrations (IC\n            <jats:sub>50<\/jats:sub>\n            s) for the two compounds ranged from 0.5 nM to 6,701 nM. The compounds also inhibited EV, including coxsackie A and B viruses (IC\n            <jats:sub>50<\/jats:sub>\n            = 773 to 3,608 nM) and echoviruses (IC\n            <jats:sub>50<\/jats:sub>\n            = 193 to 5,155 nM). BTA39 only inhibited poliovirus strain WM-1 at 204 nM, and BTA188 only inhibited poliovirus strain Chat at 82 nM. EV 71 was inhibited by BTA39 and BTA188, with IC\n            <jats:sub>50<\/jats:sub>\n            s of 1 and 82 nM, respectively. Both compounds were relatively nontoxic in actively growing cells (50% cytotoxic doses, \u22654,588 nM). These data suggest that these oxime ethers warrant further investigation as potential agents for treating selected PV infections.\n          <\/jats:p>","DOI":"10.1128\/aac.48.5.1766-1772.2004","type":"journal-article","created":{"date-parts":[[2004,4,22]],"date-time":"2004-04-22T19:58:16Z","timestamp":1082663896000},"page":"1766-1772","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":59,"title":["In Vitro Activity of Expanded-Spectrum Pyridazinyl Oxime Ethers Related to Pirodavir: Novel Capsid-Binding Inhibitors with Potent Antipicornavirus Activity"],"prefix":"10.1128","volume":"48","author":[{"given":"D. L.","family":"Barnard","sequence":"first","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. D.","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. F.","family":"Smee","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. W.","family":"Sidwell","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. G. W.","family":"Watson","sequence":"additional","affiliation":[{"name":"Biota Holdings Ltd., Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P. T.","family":"Tucker","sequence":"additional","affiliation":[{"name":"Biota Holdings Ltd., Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A. R.","family":"Reece","sequence":"additional","affiliation":[{"name":"Biota Holdings Ltd., Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.64.3.1117-1123.1990"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.1.100"},{"key":"e_1_3_2_4_2","first-page":"179","year":"1993","unstructured":"Andries, K. 1993. Discovery of pirodavir, a broad-spectrum inhibitor of rhinoviruses, p. 179-209. In J. Adams and V. J. Merluzzi (ed.), The search for antiviral drugs. Birkhauser, Boston, Mass.","journal-title":"The search for antiviral drugs."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/095632020101200405","volume":"12","year":"2001","unstructured":"Barnard, D. L., V. D. Stowell, K. L. Seley, V. R. Hegde, S. R. Das, V. P. Rajappan, S. W. Schneller, D. F. Smee, and R. W. Sidwell. 2001. Inhibition of measles virus replication by 5\u2032-nor carbocyclic adenosine analogues. Antivir. Chem. Chemother.12:241-250.","journal-title":"Antivir. Chem. Chemother."},{"key":"e_1_3_2_6_2","first-page":"777","year":"2001","unstructured":"Couch, R. B. 2001. Rhinoviruses, p. 777-797. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed., vol. 1. Lippincott Williams and Wilkins, Philadelphia, Pa.","journal-title":"Fields virology, 4th ed., vol. 1."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/095632029700800502","volume":"8","year":"1997","unstructured":"Diana, G. D., and D. C. Pevear. 1997. Antipicornavirus drugs: current status. Antivir. Chem. Chemother.8:401-408.","journal-title":"Antivir. Chem. Chemother."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9805384"},{"key":"e_1_3_2_9_2","first-page":"487","year":"1987","unstructured":"Giranda, V. L., and G. D. Diana. 1987. Rhinoviral capsid-binding inhibitors: structural basis for understanding rhinoviral biology and for drug design, p. 487-524. In P. Veerapandian (ed.), Structure-based design. Marcel Dekker, Inc., New York, N.Y.","journal-title":"Structure-based design."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.290"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.69.7.4189-4197.1995"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"1512S","DOI":"10.1093\/jn\/130.5.1512S","volume":"130","year":"2000","unstructured":"Jackson, J. L., E. Lesho, and C. Peterson. 2000. Zinc and the common cold: a meta-analysis revisited. J. Nutr.130:1512S-1515S.","journal-title":"J. Nutr."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(00)00106-6"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.20.11000"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.mi.46.100192.003223","volume":"46","year":"1992","unstructured":"McKinlay, M. A., D. C. Pevear, and M. G. Rossmann. 1992. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu. Rev. Microbiol.46:635-654.","journal-title":"Annu. Rev. Microbiol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0306-9877(96)90259-5","volume":"46","year":"1996","unstructured":"Novick, S. G., J. C. Godfrey, N. J. Godfrey, and H. R. Wilder. 1996. How does zinc modify the common cold? Clinical observations and implications regarding mechanisms of action. Med. Hypotheses46:295-302.","journal-title":"Med. Hypotheses"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2444"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2109"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00206-6"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1021\/jm970423k","volume":"40","year":"1997","unstructured":"Tebbe, M. J., W. A. Spitzer, F. Victor, S. C. Miller, C. C. Lee, T. R. Sattelberg, Sr., E. McKinney, and J. C. Tang. 1997. Antirhino\/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice. J. Med. Chem.40:3937-3946.","journal-title":"J. Med. Chem."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1021\/jm0202876","volume":"46","year":"2003","unstructured":"Watson, K. G., R. N. Brown, R. Cameron, D. K. Chalmers, S. Hamilton, B. Jin, G. Y. Krippner, A. Luttick, D. B. McConnell, P. A. Reece, J. Ryan, P. C. Stanislawski, S. P. Tucker, W. Y. Wu, D. L. Barnard, and R. W. Sidwell. 2003. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J. Med. Chem.46:3181-3184.","journal-title":"J. Med. Chem."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.5.1766-1772.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.5.1766-1772.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:17:04Z","timestamp":1645467424000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.5.1766-1772.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1128\/AAC.48.5.1766-1772.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.5.1766-1772.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"2003-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-01-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}